Compare ZVRA & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | ISD |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 488.5M |
| IPO Year | 2015 | N/A |
| Metric | ZVRA | ISD |
|---|---|---|
| Price | $9.04 | $14.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.71 | N/A |
| AVG Volume (30 Days) | ★ 547.1K | 81.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | ★ 34.27 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $23,612,000.00 | N/A |
| Revenue This Year | $333.64 | N/A |
| Revenue Next Year | $44.19 | N/A |
| P/E Ratio | $7.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.19 | $11.82 |
| 52 Week High | $13.16 | $14.79 |
| Indicator | ZVRA | ISD |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 36.49 |
| Support Level | $8.61 | $13.97 |
| Resistance Level | $8.99 | $14.34 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 71.05 | 12.53 |
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.